Psychiatry Research
Volume 105, Issue 1 , Pages 107-115 , 15 December 2001

Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome

  • Worrawat Chanpattana

      Affiliations

    • Department of Psychiatry, Srinakharinwirot University, 681 Samsen, Dusit, Bangkok 10300, Thailand
    • Corresponding Author InformationCorresponding author. Tel.: +66-2-292-2192; fax: +66-2-292-2211
    • ,
  • M.L Somchai Chakrabhand

      Affiliations

    • Department of Mental Health, Ministry of Health, Nonthaburi, Thailand

Received 5 December 2000 ,Revised 5 June 2001 ,Accepted 21 June 2001.

References 

  1. Agarwal AK, Andrade C, Reddy MV. The practice of ECT in India: issues relating to the administration of ECT. Indian Journal of Psychiatry. 1992;34:285–297
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: APA; 1994;
  3. Baudis P. Elektrokonvulsivni lecba v Ceske republice v letech 1981–1989. Ceskeslovenska Psychiatrie. 1992;88:41–47
  4. Bilder RM, Lipschutz-Broch L, Rieder RO. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophrenia Bulletin. 1992;18:437–448
  5. Breier A, Wolkowitz OM, Doran AR. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. American Journal of Psychiatry. 1987;144:1549–1555
  6. Cerletti U, Bini L. Un neuvo metodo di shockterapie ‘L'elettro-shock’. Bolletino Accademia Medica Roma. 1938;64:136–138
  7. Chanpattana W, Chakrabhand S, Kongsakon R, Techakasem P, Buppanharun W. Short-term effect of combined ECT and neuroleptic therapy in treatment-resistant schizophrenia. Journal of ECT. 1999;15:129–139
  8. Chanpattana W, Chakrabhand S, Sackeim HA, Kitaroonchai W, Kongsakon R, Techakasem P, et al. Continuation ECT in treatment-resistant schizophrenia: a controlled study. Journal of ECT. 1999;15:178–192
  9. Chanpattana W, Chakrabhand S, Techakasem P, Prasertsuk Y. The use of stabilization period in ECT research in schizophrenia: II. Implementation. Journal of the Medical Association of Thailand. 1999;82:558–568
  10. Devanand DP, Sackeim HA, Prudic J. Electroconvulsive therapy in the treatment-resistant patient. Psychiatric Clinics of North America. 1991;14:905–923
  11. Dodwell D, Goldberg D. A study of factors associated with response to electroconvulsive therapy in patients with schizophrenic symptoms. British Journal of Psychiatry. 1989;154:635–639
  12. Fava M, Davidson RG. Definition and epidemiology of treatment-resistant depression. Psychiatric Clinics of North America. 1996;19:179–200
  13. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. Journal of Affective Disorders. 1996;36:95–105
  14. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatric Clinics of North America. 1993;16:295–312
  15. Goldberg SC. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophrenia Bulletin. 1985;11:453–456
  16. Hamilton M. Drug resistant depression: response to ECT. Pharmakopsychiatry and Neuropsychopharmacology. 1974;7:205–206
  17. Herzberg F. Prognostic variables for electro-shock therapy. Journal of General Psychology. 1954;50:79–86
  18. Johnstone EC, Crow TJ, Frith CD. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976;2:924–926
  19. Kalinowsky L, Worthing HJ. Results with electric convulsive therapy in 200 cases of schizophrenia. Psychiatric Quarterly. 1943;17:144–153
  20. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry. 1988;45:789–796
  21. Kane JM. Pharmacologic treatment of schizophrenia. Biological Psychiatry. 1999;46:1396–1408
  22. Kongsakon R, Vanichtanom R. Assessment of the differences in MMSE between neurological, psychiatric patients and normal population. Journal of Rajwithi Hospital. 1994;5:99–106
  23. Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh: E&S Livingstone; 1919;
  24. Krueger RB, Sackeim HA. Electroconvulsive therapy and schizophrenia. In:  Hirsch S,  Weinberger D editor. Schizophrenia. Oxford: Oxford University Press; 1995;p. 503–545
  25. Latey R, Fahy T. Electroconvulsive therapy in the Republic of Ireland 1982: a summary of findings. British Journal of Psychiatry. 1985;147:438–439
  26. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. British Medical Journal. 1971;iii:599–604
  27. Liddle PF. Schizophrenic syndromes, cognitive performance, and neurological dysfunction. Psychological Medicine. 1987;17:49–52
  28. Malla A. An epidemiological study of electroconvulsive therapy: rate and diagnosis. Canadian Journal of Psychiatry. 1986;31:824–830
  29. May PR. Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods. New York: Science House; 1968;
  30. Medical Research Council . Clinical trial of the depressive illness. British Medical Journal. 1965;5439:881–886
  31. Overall JF, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1962;10:799–812
  32. Pippard J, Ellam L. Electroconvulsive treatment in Great Britain, 1980. London: Gaskell; 1981;
  33. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Research. 1990;31:287–296
  34. Royal College of Psychiatrists . The ECT Handbook: The Second Report of the Royal College of Psychiatrists’ Special Committee on ECT. London: Gaskell; 1995;
  35. Sackeim HA, Decina P, Prohovnik I, Malitz S, Resor SR. Anticonvulsant and antidepressant properties of electroconvulsive therapy: a proposed mechanism of action. Biological Psychiatry. 1983;18:1301–1310
  36. Sackeim HA, Decina P, Prohovnik I, Malitz S. Seizure threshold in electroconvulsive therapy: effects of sex, age, electrode placement, and number of treatments. Archives of General Psychiatry. 1987;44:355–360
  37. Sackeim HA, Decina P, Portnoy S, Neeley P, Malitz S. Studies of dosage, seizure threshold, and seizure duration in ECT. Biological Psychiatry. 1987;22:249–268
  38. Sackeim HA, Devanand DP, Prudic J. Stimulus intensity, seizure threshold, and seizure duration: impact on the efficacy and safety of electroconvulsive therapy. Psychiatric Clinics of North America. 1991;14:803–843
  39. Taylor PJ, Fleminger JJ. ECT for schizophrenia. Lancet. 1980;1:1380–1382
  40. Thompson JW, Blaine JD. Use of ECT in the United States in 1975 and 1980. American Journal of Psychiatry. 1987;144:557–562
  41. Thompson JW, Weiner RD, Myers CP. Use of ECT in the United States in 1975, 1980, and 1986. American Journal of Psychiatry. 1994;151:1657–1661
  42. Tollefson GD. Cognitive function in schizophrenic patients. Journal of Clinical Psychiatry. 1996;57(suppl 11):31–39
  43. Wirshing DA, Marshall BD, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. American Journal of Psychiatry. 1999;156:1374–1379
  44. World Health Organization . Schizophrenia: An International Follow-Up Study. New York: John Wiley & Sons; 1979;

☆ Presented at the 154th American Psychiatric Association Annual Meeting, May 8, 2001, Convention Center, New Orleans, Louisiana.

PII: S0165-1781(01)00321-3

Psychiatry Research
Volume 105, Issue 1 , Pages 107-115 , 15 December 2001

Article Tools